Unknown

Dataset Information

0

Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.

ABSTRACT: The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described. Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets. A physicochemistry-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacology led to the discovery of 16h. Compound 16h has a superior balance of ghrelin receptor pharmacology and off-target selectivity. On the basis of its promising pharmacological and safety profile, 16h was advanced to human clinical trials.

SUBMITTER: Bhattacharya SK 

PROVIDER: S-EPMC4027753 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described. Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated insulin secretion in human whole and dispersed islets. A physicochemistry-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacology  ...[more]

Similar Datasets

Unknown Synthesis of PF-6870961, a major hydroxy metabolite of the novel ghrelin receptor inverse agonist PF-5190457.
| S-EPMC9837661 | biostudies-literature
Unknown Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
| S-EPMC4025788 | biostudies-other
Unknown Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.
| S-EPMC4018168 | biostudies-literature
Unknown Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
| S-EPMC4360146 | biostudies-literature
Unknown The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study.
| S-EPMC6215751 | biostudies-literature
Unknown A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers.
| S-EPMC8855888 | biostudies-literature
Unknown Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
| S-EPMC4007909 | biostudies-other
Unknown Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.
| S-EPMC4018057 | biostudies-literature
Unknown Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
| S-EPMC3109749 | biostudies-literature
Unknown Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
| S-EPMC4025659 | biostudies-literature